Role of liver biopsy in the assessment of non-alcoholic fatty liver disease

European Journal of Gastroenterology and Hepatology

Volumn 16, Issue 11, 2004, Pages 1107-1115

  Hübscher, Stefan G ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Histological grading and staging; Liver biopsy; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis

Indexed keywords

ALCOHOLIC FATTY LIVER; CHRONIC HEPATITIS; CLINICAL FEATURE; DISEASE COURSE; DISEASE SEVERITY; HISTOLOGY; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER INJURY; MALLORY BODY; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

ALCOHOLISM; BIOPSY; CHRONIC DISEASE; FATTY LIVER; HEPATITIS; HUMANS; LIVER; LIVER CIRRHOSIS; PROGNOSIS;

EID: 8444233581     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200411000-00004     Document Type: Review

References (48)

1. Reid AE. Nonalcoholic steatohepatitis. Gastroenterology 2001; 121:710-723. A comprehensive review of non-alcoholic steatohepatitis. In addition to describing clinical and histological features of NASH, there is a detailed discussion of risk factors, pathogenetic mechanisms and the natural history of NASH.
2. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 2003; 37:1202-1219. A consensus document based on discussions held at an AASLD single topic conference on NASH. The document represents an important attempt to clarify definitions relating to the clinico-pathological spectrum of non-alcoholic fatty liver disease. A scheme for grading and staging NASH is proposed, based on a modified version of the system devised by Brunt et al. [16].
3. Spaulding L, Trainer T, Janiec D. Prevalence of non-alcoholic steatohepatitis in morbidly obese subjects undergoing gastric bypass. Obes Surg 2003; 13:347-349.
4. Banner BF, Savas L, Zivny J, Tortorelii K, Bonkovsky HL. Ubiquitin as a marker of cell injury in nonalcoholic steatohepatitis. Am J Clin Pathol 2000; 114:860-866.
5. Zatloukal K, Stumptner C, Fuchsbichler A, Heid H, Schnoelzer M, Kenner L, et al. p62 is a common component of cytoplasmic inclusions in protein aggregation diseases. Am J Pathol 2002; 160:255-263.
6. Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart LJ, Lindor KD, et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003; 125:437-443. A recent study describing the importance of apoptosis as a mechanism of liver cell death in NASH. Markers of apoptosis and expression of the Fas receptor were significantly increased in NASH biopsies compared to normal controls and biopsies with simple steatosis, a finding which may have diagnostic and therapeutic implications.
7. Caldwell SH, Swerdlow RH, Khan EM, Iezzoni JC, Hespenheide EE, Parks JK, et al. Mitochondrial abnormalities in non-alcoholic steatohepatitis. J Hepatol 1999; 31:430-434.
8. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120:1183-1192. Mitochondrial defects in the form of loss of cristae and paracrystalline inclusions were found to be present in patients with NASH, but not those with fatty change alone. This observation has implications for the histological diagnosis of NASH and for understanding mechanisms for hepatocellular injury.
9. Lefkowitch JH, Haythe JH, Regent N. Kupffer cell aggregation and perivenular distribution in steatohepatitis. Mod Pathol 2002; 15:699-704.
10. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11:74-80.
11. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999; 29:664-669. The importance of NASH as a risk factor for 'cryptogenic' cirrhosis was identified in this study. The lack of conspicuous histological features of NASH in cases where cirrhosis has supervened was also noted.
12. Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology 2000; 32:689-692.
13. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123:134-140.
14. Ratziu V, Bonyhay L, Di Martino V, Charlotte F, Cavallaro L, Sayegh-Tainturier MH, et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 2002; 35:1485-1493.
15. Shimada M, Hashimoto E, Taniai M, Hasegawa K, Okuda H, Hayashi N, et al. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol 2002; 37:154-160.
16. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94:2467-2474. This represents the first attempt to devise a scheme for grading and staging the histological changes occurring in NASH. Although there are problems with applying certain components of the grading scheme, the Brunt system is now being widely used in clinico-pathological studies. It will no doubt form the basis for future studies investigating new approaches to the histological classification of fatty liver disease.
17. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 2001; 21:3-16.
18. Ayata G, Gordon FD, Lewis WD, Pomfret E, Pomposelli JJ, Jenkins RL, Khettry U. Cryptogenic cirrhosis: clinicopathologic findings at and after liver transplantation. Hum Pathol 2002; 33:1098-1104.
19. Roskams T, Desmet V. Ductular reaction and its diagnostic significance. Semin Diagn Pathol 1998; 15:259-269.
20. Younossi ZM, Gramlich T, Bacon BR, Matteoni CA, Boparai N, O'Neill R, McCullough AJ. Hepatic iron and nonalcoholic fatty liver disease. Hepatology 1999; 30:847-850.
21. Chitturi S, Weltman M, Farrell GC, McDonald D, Kench J, Liddle C, et al. HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity. Hepatology 2002; 36:142-149.
22. Chitturi S, George J. Interaction of iron, insulin resistance, and nonalcoholic steatohepatitis [Review]. Curr Gastroenterol Rep 2003; 5:18-25. The role of iron overload as a co-factor for progressive liver injury in patients with NASH has been the subject of controversy. This article reviews previous studies investigating this matter and concludes that hepatic iron overload is unlikely to play an important role in the pathogenesis of liver fibrosis in patients with NASH.
23. Roberts EA. Steatohepatitis in children. Best Pract Res Clin Gastroenterol 2002; 16:749-765.
24. Roberts EA. Nonalcoholic steatohepatitis in children. Curr Gastroenterol Rep 2003; 5:253-259.
25. Baldridge AD, Perez-Atayde AR, Graeme-Cook F, Higgins L, Lavine JE. Idiopathic steatohepatitis in childhood: a multicenter retrospective study. J Pediatr 1995; 127:700-704.
26. Manton ND, Lipsett J, Moore DJ, Davidson GP, Bourne AJ, Couper RT. Non-alcoholic steatohepatitis in children and adolescents. Med J Aust 2000; 173:476-479.
27. Rashid M, Roberts EA. Nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr 2000; 30:48-53. Although there had been occasional previous reports this was the first large study to recognize NASH as an important complication of childhood obesity. The study also recognizes that paediatric NASH may have different histological features compared to the typical changes occurring in the adult population.
28. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123:745-750.
29. Joy D, Thava VR, Scott BB. Diagnosis of fatty liver disease: is biopsy necessary? Eur J Gastroenterol Hepatol 2003; 15:539-543.
30. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30:1356-1362.
31. Day CP. Non-alcoholic steatohepatitis (NASH): where are we now and where are we going? Gut 2002; 50:585-588. A succinct review of recent developments in the NASH field, including a discussion of identifying patients who are likely to benefit most from having a liver biopsy.
32. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35:373-379.
33. Pagano G, Pacini G, Musso G, Gambino R, Mecca F, Depetris N, et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 2002; 35:367-372.
34. Lee RG. Nonalcoholic steatohepatitis: tightening the morphological screws on a hepatic rambler. Hepatology 1995; 21:1742-1743. This brief review article is now several years old, but makes a number of important points relating to the need for strict criteria for making a histological diagnosis of NASH.
35. Diehl AM, Goodman Z, Ishak KG. Alcohol-like liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury. Gastroenterology 1988; 95:1056-1062.
36. Itoh S, Yougel T, Kawagoe K. Comparison between nonalcoholic steatohepatitis and alcoholic hepatitis. Am J Gastroenterol 1987; 82:650-654.
37. Brunt EM. Alcoholic and nonalcoholic steatohepatitis. Clin Liver Dis 2002; 6:399-420.
38. Farrell GC. Drug-induced steatohepatitis. In: Farrell GC (editor). Drug-induced Liver Disease. Edinburgh: Churchill Livingstone; 1994, pp. 431-438.
39. Clouston AD, Powell EE. Interaction of non-alcoholic fatty liver disease with other liver diseases. Best Pract Res Clin Gastroenterol 2002; 16:767-781.
40. Brunt EM, Ramrakhiani S, Cordes BG, Neuschwander-Tetri BA, Janney CG, Bacon BR, et al. Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease. Mod Pathol 2003; 16:49-56. This study recognizes the increasing prevalence of steatohepatitis occurring in association with other causes of chronic liver disease, particularly hepatitis C. This has important implications for liver biopsy assessment in patients where the main clinical diagnosis is something other than fatty liver disease.
41. Ong JP, Younossi ZM, Speer C, Olano A, Gramlich T, Boparai N. Chronic hepatitis C and superimposed nonalcoholic fatty liver disease. Liver 2001; 21:266-271.
42. Monto A, Alonzo J, Watson JJ, Grunfeld C, Wright TL. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology 2002; 36:729-736.
43. Ramalho F. Hepatitis C virus infection and liver steatosis. Antiviral Res 2003; 60:125-127.
44. Ortiz V, Berenguer M, Rayon JM, Carrasco D, Berenguer J. Contribution of obesity to hepatitis C-related fibrosis progression. Am J Gastroenterol 2002; 97:2408-2414.
45. Langman G, Hall PM, Todd G. Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury. J Gastroenterol Hepatol 2001; 16:1395-1401.
46. Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995; 22:1714-1719. An early study identifying the prognostic importance of liver biopsy in non-alcoholic fatty liver disease. The benign, non-progressive nature of pure fatty liver is contrasted with the potential for progressive liver injury when features of steatohepatitis are present.
47. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116:1413-1419. Another study investigating the natural history of NAFLD, confirming important differences in behaviour between simple steatosis and steatohepatitis. The importance of applying strict criteria for the histological diagnosis of steatohepatitis is also confirmed.
48. Harrison SA, Torgerson S, Hayashi PH. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol 2003; 98:2042-2047.